Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
11/2003
11/27/2003WO2003064622A3 Aggrecanase molecules
11/27/2003WO2003059270A3 Method for reducing morbidity and mortality in critically ill patients
11/27/2003WO2003053354A3 Fused cyclic modulators of nuclear hormone receptor function
11/27/2003WO2003053336A3 Methods for the treatment of peripheral neural and vascular ailments
11/27/2003WO2003051879A8 Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
11/27/2003WO2003042344A3 Apo2 ligand/trail formulations
11/27/2003WO2003040119A8 Angiogenesis inhibitors
11/27/2003WO2003039446A3 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
11/27/2003WO2003034275A3 Chimeric glycosylphosphatidylinositol containing peptides
11/27/2003WO2003031578A3 Mammalian c-type lectins
11/27/2003WO2003029276A3 Copolymers for suppression of autoimmune diseases, and methods of use
11/27/2003WO2003022852A3 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
11/27/2003WO2003020759A3 A caspase- 8 binding protein, its preparation and use
11/27/2003WO2003015717A3 Tyrosine kinase inhibitors
11/27/2003WO2003014064A8 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
11/27/2003WO2003013590A8 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
11/27/2003WO2003009802A3 Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide
11/27/2003WO2003008443A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/27/2003WO2003006425A3 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
11/27/2003WO2003005971A3 Tetracycline compounds having target therapeutic activities
11/27/2003WO2002092004A8 Use of hmg fragment as anti-inflammatory agents
11/27/2003WO2002086156A3 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
11/27/2003WO2002086113A3 Enzyme and snp marker for disease
11/27/2003WO2002085940A3 New polynucleotides and polypeptides of the erythropoietin gene
11/27/2003WO2002079170A3 Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them
11/27/2003WO2002078730A3 Use of neublastin polypeptides for treating neuropathic pain
11/27/2003WO2002074735A3 Biurethane derivatives
11/27/2003WO2002072095A3 Tiotropium salts for treating inflammatory diseases
11/27/2003WO2002067903A3 Compositions and methods of manufacture for oral dissolvable dosage forms
11/27/2003WO2002060393B1 Proteoglycan compositions for treatment of inflammatory conditions
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003WO2002049625A3 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/27/2003US20030221199 Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
11/27/2003US20030220504 Forming a phenyl-thiazoles chemical intermediates for making antioxidants, ferrielectric liquid crystal dopant, picornaviral viricides, antiinflammatory agents, anti-asthma agents, and fibringoen antagonists
11/27/2003US20030220494 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/27/2003US20030220489 29 human secreted proteins
11/27/2003US20030220468 Modified forms of pharmacologically active agents and uses therefor
11/27/2003US20030220397 Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
11/27/2003US20030220390 Carbocyclic oxy amines such as 2-benzylidene-6-dimethylamino methylcyclohexanone, used as analgesics
11/27/2003US20030220389 Tertiary amines such as 2-dimethylaminomethyl-1-(3-methoxy-phenyl)-6-methylcyclohexanol, used as analgesics
11/27/2003US20030220375 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
11/27/2003US20030220373 Therapeutic uses of PPAR mediators
11/27/2003US20030220372 Imidazole compounds as anti-inflammatory and analgesic agents
11/27/2003US20030220371 Administering to a mammal an aromatic or heteroaromatic ring substituted triazole derivative to treat the conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, and obesity
11/27/2003US20030220367 Administering a therapeutical carbamate derivative to a patient as prostaglandin IP (12 or PGI2) antagonists
11/27/2003US20030220360 Tricyclic condensed heterocyclic compounds containing o, s in the ring, and atleast one hydroxy group, useful as antiasthmatic drugs
11/27/2003US20030220359 Substituted pyrimidine-sulfonamide derivatives are used as endothelin receptor antagonists
11/27/2003US20030220353 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/27/2003US20030220347 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
11/27/2003US20030220345 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones
11/27/2003US20030220341 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
11/27/2003US20030220339 Heterocyclic arylsulfonamidobenzylic compounds
11/27/2003US20030220330 Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
11/27/2003US20030220325 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling
11/27/2003US20030220323 Such as (2-(4-(2-(1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy)-1-phenyl-ethyl) -piperazin-1-yl)-ethoxy)-acetic acid; for prevention and/or treatment of conditions associated with pathogical levels of substance P
11/27/2003US20030220322 Substituted 3,4-dihydro-pyrimido[1,2a]pyrimidines and 3,4-dihydro-pyrazino[1,2a]pyrimidines, and methods for their preparation and use
11/27/2003US20030220319 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders
11/27/2003US20030220318 New phenylalanine derivatives
11/27/2003US20030220306 Transcripts harboring inton 1, or fragment thereof; preventing or treating Alzheimer's Disease; ameliorating a neurodegenerative condition; modulating amyloid precursor protein; selectively inhibiting COX-3 or PCOX-1a activity
11/27/2003US20030220303 GABAB Receptor Agonists; used to treat gastrointestinal disorders, especially GERD
11/27/2003US20030220297 Phosphorus-containing compounds and uses thereof
11/27/2003US20030220277 Methylation of plasmid vectors
11/27/2003US20030220268 New phenylalanine derivatives
11/27/2003US20030220256 Truncated 24kDa basic fibroblast growth factor
11/27/2003US20030220248 Use of MP52 or MP121 for the treatment and prevention of diseases of the nervous system
11/27/2003US20030220228 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/27/2003US20030219898 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
11/27/2003US20030219875 Albumin fusion proteins
11/27/2003US20030219864 Novel variants of RANKL protein
11/27/2003US20030219439 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders
11/27/2003US20030219438 Human antibodies that bind human TNFalpha
11/27/2003US20030219413 Method for overexpression of zwitterionic polysaccharides
11/27/2003US20030219401 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
11/27/2003US20030219375 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003US20030217908 Method and apparatus for transferring substrates
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
11/27/2003CA2486483A1 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
11/27/2003CA2486157A1 Opioid and opioid-like compounds and uses thereof
11/27/2003CA2486147A1 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
11/27/2003CA2486141A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003CA2486138A1 Methods of using thiazolidinedithione derivatives
11/27/2003CA2486133A1 Injection formulation
11/27/2003CA2486106A1 Compounds and methods for inhibiting selectin-mediated function
11/27/2003CA2486092A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor
11/27/2003CA2485933A1 5-ethylimidarotriazones
11/27/2003CA2485214A1 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
11/27/2003CA2485212A1 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
11/27/2003CA2484702A1 Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/27/2003CA2484671A1 Cyanoguanidine prodrugs
11/27/2003CA2484646A1 Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
11/27/2003CA2484631A1 Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
11/27/2003CA2484308A1 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
11/27/2003CA2484233A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
1 ... 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 ... 1272